CD123

Product List

Here are the products related to CD123 CAR, so you can choose the one that will be useful for your research project!

Background

IL-3 is a pleiotropic interleukin cytokine produced primarily by activated T lymphocytes. It mainly regulates the function and production of hematopoietic cells and immune cells. The IL-3 receptor (IL-3R) is a heterodimer composed of α and β chains, and CD123 is the α chain of the interleukin 3 receptor (IL-3Rα). Studies have shown that CD123 is overexpressed on a variety of tumor cells and plays a role in promoting the excessive proliferation of tumor cells. As a result, CD123 has emerged as an attractive novel therapeutic target for hematological malignancies.

Fig.1 Schematic diagram of the structure of CD123.¹

Associated Diseases

Plasmacytoid Dendritic Cell Tumor

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia/Lymphoma

Hairy Cell Leukemia

Systemic Mastocytosis

Anti-CD123 CAR-T Services

CD123 CAR Design & Construction

With an advanced technology platform and strong scientific research strength, Creative Biolabs constructs effective and stable CD123 CAR-T cells for you through CAR molecular structure design, T-cell transfection, CAR-T cell identification, etc.

Fig.2 Schematic diagram of CD123 CAR construction.²

Anti-CD123 CAR-T In Vitro Assays

Anti-CD123 CAR-T Cytokine Release Test

Cytokine Release Syndrome (CRS) can cause microvascular system damage, and cytokines such as IFN-γ and IL-6 are released in large quantities, which can promote each other with the coagulation activation process, and finally form multi-organ failure. There are many cytokines associated with CRS, but a few are particularly critical, namely IL-2, IFN-γ, IL-6, and IL-10.

Fig.3 IFN-γ levels of CD123 CAR-T in the supernatant after cell co-culture.²

Anti-CD123 CAR-T In Vitro Cytotoxicity Assay

Creative Biolabs offers cytotoxicity assays to measure the cancer cell-killing capacity of effector cells. The four most commonly used assays are chromium (51 chromium) release assays, luciferase-mediated bioluminescence imaging assays, impedance-based assays, and flow cytometry assays.

Fig.4 Assessment of the CD123 CAR-T cytotoxicity. The results showed a significant reduction in CD123 CAR-T-induced CB cell death.²

Anti-CD123 CAR-T In Vivo Assays

Anti-CD123 CAR-T Cell Therapy Animal Models

Due to species differences, there are problems such as species specificity of CAR-T cells and tumor targets, xenograft-versus-host responses, and difficulties in mimicking human immune responses in animals, and the selection of appropriate animal models is crucial for the proof of concept of CAR-T cell function. Creative Biolabs offers humanized mouse models to help you test information about the efficacy, distribution, and proliferation characteristics of CAR-T cells in vivo.

Fig.5 In vivo study of CD123 CAR-T in NSG mice.²

Efficacy Test of Anti-CD123 CAR-T

In vivo efficacy assessment is essential to study the factors that influence the efficacy of CAR-T. Creative Biolabs offers a range of in vivo pharmacodynamic evaluation services for CD123 CAR-T to provide a scientific basis for your preclinical studies.

Fig.6 Efficacy of CD123 CAR-T treated NSG mice. The results showed that CD123 CAR-T effectively eliminated leukemia.²

Viability Study of Anti-CD123 CAR-T

Creative Biolabs offers a range of CD123 CAR-T viability study services, including but not limited to in vivo proliferation and survival assays, T cell migration and distribution, memory T cell responses, and more.

Fig.7 Survival curves of CD123 CAR-T treated with PDX-AML2. The results showed that CD123 CAR-T treatment significantly prolonged the overall survival of PDX-AML2.²

References

1. El Achi, Hanadi.; et al. "CD123 as a biomarker in hematolymphoid malignancies: Principles of detection and targeted therapies." Cancers. (2020) 12,11 3087.
2. Sugita, M.; et al. "Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia." Nat Commun. (2022) 13, 2227.